InterCure reported first-half 2025 revenue of NIS 130 million, its eleventh straight period of positive adjusted EBITDA at 10% of sales, and NIS 12 million in positive operating cash flow, despite a modest net loss of NIS 1.8 million. Operations resumed at its Nir Oz facility, more than 40 SKUs hit the market in its first major post-2023 launch wave, and the company received NIS 81 million in advances related to war-damage compensation. Strategically, InterCure signed a share purchase agreement to acquire Botanico (ISHI), securing the exclusive supply of premium products under Flowery and other U.S. brands that are expected to add tens of millions of shekels in revenue.
The question for senior pharma leaders is whether InterCure is outlining a durable, pharma-grade cannabis playbook or a near-term rebound supported by extraordinary factors. The vertically integrated, GMP-centric model, pharmacy distribution, and branded genetics portfolio create a clear route to scale. Yet year-over-year revenue growth was just 3%, highlighting how quickly operational execution must now translate into share gains, margin expansion, and repeat prescribing. With adjusted profitability resilient but headline profit still negative, the durability of cash generation—absent compensation effects—will be scrutinized by partners and payers alike.
This matters now because product availability, consistency, and medical credibility are becoming the decisive currency in cannabis-adjacent therapeutics. Patients in Israel are regaining access to stable, pharmacy-dispensed products after supply disruptions, while clinicians face a proliferation of SKUs that requires tighter medical guidance and outcomes data. For payers, an expanding shelf does not equal reimbursement; formulary discipline will hinge on real-world evidence, standardized dosing, and clearer positioning by indication and patient segment. InterCure’s ability to convert a broad portfolio into clinically coherent pathways will influence prescribing patterns, persistence, and budget impact.
The ISHI deal is equally about positioning ahead of possible U.S. rescheduling and the globalization of cannabis brands. Cross-border access to premium U.S. genetics and cultivation know-how can differentiate quality and consistency, while the pharmacy-channel footprint and GMP manufacturing align with the direction of travel in Europe and Israel. This mirrors broader industry trends: selective, capability-driven M&A rather than balance-sheet land grabs; a pivot from retail-led narratives to evidence-led adoption; and intensifying pressure to generate outcomes comparable to established pain, neuropsychiatric, and oncology supportive-care standards. If rescheduling advances in the U.S., capital may reflow to assets with pharmaceutical discipline, strengthening the case for international licensing, data generation, and BD partnerships.
The next twelve months will test whether InterCure can turn SKU proliferation into sustained script volume, lift gross margins through scale and mix, and translate U.S. brand access into measurable share outside North America. For Medical Affairs, the mandate is to build real-world datasets that narrow variability, support dose titration, and anchor payer conversations in outcomes rather than anecdotes. For Commercial, the task is indication-specific positioning and pharmacy pull-through. The sharper question is whether cannabis companies that act like pharma—GMP-first, evidence-forward, and BD-enabled—can outpace retail-native competitors as regulators and payers raise the bar.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
